Patent application number | Description | Published |
20090118279 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF - The present invention relates to a compound represented by formula (I): | 05-07-2009 |
20090169567 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF - A compound represented by general formula (I): | 07-02-2009 |
20090192182 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF - A compound represented by general formula (I): | 07-30-2009 |
20090325992 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF - A compound represented by general formula (I): | 12-31-2009 |
20120156219 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF - The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. | 06-21-2012 |
20120207765 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - A compound represented by general formula (I): | 08-16-2012 |
20120328627 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - The present invention relates to a compound represented by formula (I): | 12-27-2012 |
20130245074 | NOVEL COMPOUND AND MEDICAL USE THEREOF - Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa. | 09-19-2013 |
20140072576 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - The present invention relates to a compound represented by formula (I): | 03-13-2014 |
20140187630 | NOVEL COMPOUND AND MEDICAL USE THEREOF - Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa. | 07-03-2014 |